ATNM
What one share of Actinium Pharmaceuticals holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address significant unmet medical needs in oncology. We are focused on employing a biology-driven approach to develop differentiated, first-in-class radiopharmaceutical therapeutics for patients with solid tumors and hematologic malignancies.
Actinium Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | $0.36 |
|---|---|
| Cash and investments | $1.16 |
| Book value | $0.96 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2011 | $0.00 | −$128.89 | — | −$19.37 | — | — |
| 2012 | — | −$227.31 | $0.06 | −$141.78 | — | — |
| 2013 | — | −$14.21 | $0.02 | −$8.32 | — | −$1.90 |
| 2014 | — | −$27.07 | $0.17 | −$15.90 | — | −$1.92 |
| 2015 | — | −$16.53 | $0.04 | −$14.62 | — | $14.96 |
| 2016 | — | −$15.06 | $0.04 | −$12.91 | — | $9.68 |
| 2017 | — | −$11.96 | $0.01 | −$9.70 | — | $5.12 |
| 2018 | — | −$6.69 | $0.03 | −$5.85 | — | $2.29 |
| 2019 | — | −$4.40 | $0.01 | −$4.33 | — | $1.03 |
| 2020 | — | −$1.83 | $0.02 | −$1.80 | — | $3.50 |
| 2021 | $0.06 | −$1.20 | $0.01 | −$1.02 | — | $3.32 |
| 2022 | $0.04 | −$1.37 | $0.02 | $0.34 | — | $2.59 |
| 2023 | $0.00 | −$1.83 | $0.01 | −$1.78 | — | $1.32 |
| 2024 | — | −$1.27 | $0.00 | −$1.10 | — | $1.05 |
| 2025 | $0.00 | −$1.09 | $0.00 | −$0.79 | — | $0.25 |